Open Access

Regulatory T cells in induced sputum of asthmatic children: association with inflammatory cytokines

Multidisciplinary Respiratory Medicine20105:22

https://doi.org/10.1186/2049-6958-5-1-22

Received: 13 November 2009

Accepted: 4 December 2009

Published: 28 February 2010

Abstract

Background and objective

CD4+CD25+ regulatory T (Treg) cells play an essential role in maintaining immune homeostasis. In this study, we investigated whether the induced sputum (IS) pool and the function of CD4+CD25+ Treg cells are altered in asthma pediatric patients.

Methods

Treg activity was studied in the IS of 40 asthmatic children. CD3+ cells were analyzed for the expression of FoxP3 mRNA by real time reverse transcription-polymerase chain reaction (RT-PCR). IS cells from asthmatics and controls were stained for Treg markers and analyzed by flow cytometry. We also studied the ability of Treg cells to differentiate monocytes toward alternatively activated macrophages (AAM), and to suppress proinflammatory cytokines.

Results

(i) Mild and moderate asthmatics had significantly decreased expression of FoxP3/β-actin mRNA and decreased proportions of CD4+CD25highFoxP3+ cells compared to healthy children; (ii) patients with moderate asthma had even lower proportions of FoxP3 expression compared to mild asthmatic patients; (iii) monocytes cultured with Treg cells displayed typical features of AAM, including up-regulated expression of CD206 (macrophage mannose receptor) and CD163 (hemoglobin scavenger receptor), and an increased production of chemokine ligand 18 (CCL18). In addition, Treg cells from asthmatics have a reduced capacity to suppress LPS-proinflammatory cytokine production from monocytes/macrophages (IL-1, IL-6 and TNF-α).

Conclusion

Asthma pediatric patients display a decreased bronchial Treg population. The impaired bronchial Treg activity is associated with disease severity.

Riasssunto

Finalità

Le cellule T regolatorie (Treg) CD4+CD25+ svolgono un ruolo fondamentale nel mantenere l’omeostasi dell’immunità. In questo studio si è ricercato se la quantità e la funzione dellecellule Treg CD4+CD25+ risultino alterate nello sputo indotto (IS) di pazienti asmatici in età pediatrica

Metodi

L’attività dei Treg è stata studiata prendendo in esame l’IS di 40 bambini asmatici. Le cellule CD3+ sono state analizzate per l’espressione di FoxP3 mRNA attraverso la retro trascrizionedella reazione a catena della polimerasi (RT–PCR) in tempo reale. Le cellule dell’IS di asmatici e soggetti di controllo sono state colorate specificamente per i Treg marker e analizzatecon la citometria a flusso. Si è studiata altresì la capacità delle cellule Treg di differenziare i monociti in macrofagi alternativamente attivati (AAM), e di sopprimere citochine proinfiammatorie

Risultati

Risultati principali ottenuti: (i) Pazienti affetti da asma lieve e moderato mostravano una considerevole riduzione dell’espressione di FoxP3/β-actin mRNA e una ridotta proporzionedi cellule CD4+CD25highFoxP3+ in confronto a bambini sani; (ii) Pazienti affetti da asma moderato presentavano proporzioni ancora più basse di espressione di FoxP3 rispetto ai pazienti con asma lieve; (iii) Monociti coltivati con le cellule Treg hanno mostrato i tratti caratteristici di AAM, comprese leespressioni up-regolate di CD206 (recettore macrofagico per ilmannosio) e CD163 (recettore “scavenger” per l’emoglobina), e un aumento della produzione di ligando 18 delle chemochine(CCL18)

Inoltre i Treg degli asmatici evidenziano una ridotta capacità di sopprimere la produzione delle citochine LPS-proinfiammatorie da monociti/macrofagi (IL-1, IL-6 e TNF-α)

Conclusioni

I pazienti pediatrici con asma presentano undecremento della popolazione bronchiale di Treg. La compromissione dell’attività bronchiale dei Treg è proporzionale al livello di gravità della malattia

Keywords

Bronchial asthma CD4+CD25highFoxP3+ induced sputum inflammatory cytokines regulatory T cells

Cellule T regolatorie nello sputo indotto di bambini asmatici: associazione con le citochine infiammatorie

Parole chiave

Asma bronchiale CD4+CD25highFoxP3+ cellule regolatorie T citochine infiammatorie citochine infiammatorie citochine infiammatorie sputo indotto

Introduction

Chronic mucosal inflammation plays an essential role in the pathogenesis of asthma. Pathological pathways of asthma are observed early in childhood, bronchial inflammation being observed in infants and remodelling in younger children [1, 2]. Interactions between dendritic cells, monocytes/macrophages and lymphocytes induce, amplify or modulate the ongoing inflammation [3]. Recent studies have also investigated regulatory T (Treg) cells in asthma [4, 5], and it is possible that the recruitment of Treg cells into the airways suppresses allergic airway inflammation [6]. A recent study examining pediatric asthmatic patients found a low percentage of CD4+CD25high T cells (Tregs) in the bronchoalveolar lavage (BAL) compared to healthy controls or children treated with corticosteroids [7]. Additional studies in animal models of allergic airway inflammation have provided more insight into the role of Tregs in asthma [6, 8]. During inflammation, the interactions between CD4+CD25+ Treg cells and antigen presenting cells (APC) are likely to involve not only dendritic cells (DC) but also monocytes/macrophages which play a critical role in both innate and adaptive immunity. Indeed, these cells are able to recognize pathogens and/or "danger signals" via Toll-like receptors (TLRs) and other pattern-recognition receptors and produce a wide array of cytokines and chemokines. The initial inflammatory response is carried out by macrophages that produce high amounts of proinflammatory cytokines. These macrophages with a higher phagocytic capacity produce anti-inflammatory cytokines and are characterized by an increased expression of the mannose receptor CD206 and/or the hemoglobin scavenger receptor CD163. These cells are often referred to as M2 or alternatively activated macrophages (AAM) [9, 10]. Given the pivotal role of CD4+CD25+ Treg cells in maintaining self-tolerance, we here investigated whether the pool and the function of CD4+CD25+ Treg cells are altered in induced sputum from bronchial asthma patients. Then, we assessed a previously uncharacterized function of CD4+CD25+ FoxP3+ Treg cells, namely their ability to directly promote the alternative action of monocytes/macrophages.

Materials and methods

Study groups

Subject characteristics are shown in Table 1. Patients were under consultation at the Department of Respiratory Pediatrics of A. Mami Hospital. The diagnosis of asthma was based on a history of episodic wheezing and dyspnea. Asthma severity was classified according to GINA (Global Initiative for Asthma) criteria [11]. All patients from asthmatic groups were atopic as defined by at least two positive skin prick tests to common allergens. Asthma was classified as mild in twenty cases. These patients had no regular treatment with inhaled steroids. Eighteen other patients were suffering from moderate persistent asthma. They were treated with inhaled steroids (400-500 μg of beclomethasone daily). At sampling time, a good control of asthma was reached in all cases and the patients had no evidence of respiratory infection. Subjects with a history of respiratory infection during the previous four weeks were excluded from the study. Blood and induced sputum samples were collected from subjects during their visits to the outpatient clinics. Informed consent was obtained from all subjects' parents or guardians, and approval was obtained from our institutional review board.
Table 1

Clinical characteristics and induced sputum cell distribution of children with moderate and mild asthma and controls

Subject group: n. cases

Age: median (range)

Sex F/M

Atopy

Asthma history

Total IgE (kU/L)

Control: 20

9.75 (6 - 15)

12/8

No

No

65.7 ± 22.7

Mild asthma: 23

11.5 (5 - 16.5)

14/9

Yes

2.3 yrs (0-5 yrs)

296.7 ± 197†

Moderate asthma: 17

12 (5 - 16.5)

8/9

Yes

4.2 yrs (3-7 yrs)

385 ± 227

Age was expressed as median (range).

Definition of abbreviations: F, female; M, male.

† p < 0.005 compared to healthy controls.

Sputum induction and processing

Induced sputum was obtained as we recently reported [12]. Before sputum induction all patients inhaled salbutamol (200 μg) via a metered dose inhaler. Baseline peak expiratory flow (PEF) was measured and this was repeated following salbutamol inhalation and after each 5-minute inhalation of nebulized hypertonic saline. The procedure was stopped if the PEF fell by > 10% following saline or by > 20% at any time during the induction procedure. Solid sputum material was separated from saliva before processing as we have recently reported [12]. Briefly, selected sputum was weighed and 0.1% dithiothreitol (DTT) (Sigma-Aldrich, Poole, UK) in phosphate-buffered saline (PBS) was added at a ratio of 4 ml to 1 g sputum. The sputum was incubated with DTT at room temperature for 15 minutes on a rolling mixer. The same volume (4 ml to 1 g sputum) of PBS was added to the sputum and then filtered through 48 μm nylon gauze.

The filtrate was centrifuged at 400 g (Sorvall RT6000D, Kendro, Bishop's Stortford, UK) for 10 minutes at 4°C to pellet cells. The cells were resuspended in PBS containing 0.1% bovine serum albumin (BSA). The viability of the sample was determined by trypan blue exclusion staining (Sigma- Aldrich) in a Neubauer hemocytometer (Merck Eurolabs, Lutterworth, UK). Induced sputum cells were resuspended (2 × 105 cells/ml) in PBS and cytospin slides were prepared (Shandon cytospin; 400 rpm, 5 min), stained (Shandon Diffquick), and coded, and 500 cells were counted and expressed as % of non squamous epithelial cells. Absolute counts were generated from the differential and total counts.

Cell isolation from peripheral blood

Peripheral blood was obtained from 10 patients with moderate bronchial asthma (the same patients studied for Treg cells induced sputum) and from 7 healthy children, following informed consent. Peripheral blood mononuclear cells (PBMC) wereisolated by using density gradient centrifugation (Lymphocyte separation media, PAA Laboratories). Monocytes (> 95% purity) were isolated by using anti-CD14 microbeads or by depleting nonmonocytes (Miltenyi Biotec). CD4+ T cells (> 95% purity) were purified by using a T cell isolation kit, and CD4+CD25+ T cells were enriched with anti-CD25 microbeads (Miltenyi Biotec) resulting in > 90% CD4+CD25+ T cells with > 87% expressing FoxP3+ cells. In addition, separation of CD4+CD25high and CD4+CD25- T cells from total CD4+ T cells was performed by using MoFlo®. For flow cytometry, the following antibodies were used: anti-CD3- fluorescein isothiocyanate (FITC), anti-CD4- phycoerythrin (PE)-Cy5, anti-CD14- PE-Cy5, CD86- PE, anti-CD25-FITC (all from Beckman-Coulter), anti-CD206-PE, anti-CD25-PE (Miltenyi Biotec), and CD163-FITC (Santa Cruz Biotechnology).

Flow cytometry for Treg cells expression in induced sputum

Further separation of CD3+ T cells (negative selection by monodisperse), induced sputum (IS) cells were stained with FITC-conjugated anti-CD4, PE-conjugated anti-FoxP3 and allophycocyanin (APC)-conjugated anti-CD25 antibodies with appropriate isotype controls (all from eBiosciences, San Diego, CA, USA). Flow cytometry was performed using a fluorescence activated cell sorter (FACS) Calibur instrument with CellQuest software (Becton Dickinson, San Diego, CA, USA). List mode files were collected for 200,000 cells from each sample. CD25high cells were defined as described elsewhere [13, 14].

PBMC co-cultures of T cells and monocytes

Monocytes and T cells (2:1 ratio) were co-cultured in Roswell Park Memorial Institute (RPMI) medium 1640, supplemented with 1% penicillin/streptomycin, 1% glutamin, and 10% heat-inactivated FCS. Monocytes (5 × 105/ml) were cultured in either 200- or 500-μl cultures without T cells (monocytes), with CD4+CD25- T cells or CD4+CD25+ T cells (CD25+) for 40 h in the presence of 50 ng/ml anti-CD3 mAb (OKT3, Ortho Biotech), after which the different cultures were stimulated for 24 h with Lipopolysaccharide (LPS) 50 ng/ml (Sigma); this was found to be the optimal concentration out of a dose range (0-100 ng/ml) to stimulate monocytes for interleukin (IL)-6 and tumor necrosis factor (TNF)-α production.

Detection of cytokines and chemokines

IL-6, TNF-α (Invitrogen), CCL18 (R & D Systems), were measured by ELISA, and IL-1β, was measured by Luminex (Upstate) by using a Luminex 100 system, according to the manufacturer's instructions.

Statistical analysis

Statistical analysis was performed with GraphPad Prism 4.03 software by using Wilcoxon matched paired tests or impaired t-test. P values < 0.05 were considered significant.

Results

The proportion of Treg in induced sputum from bronchial asthma

As shown in Figure 1A, patients with bronchial asthma (mild asthma and moderate asthma) had significantly decreased gene expression of the transcriptional factor FoxP3 in CD3+ cells compared to healthy children (mean ± SD: 5.40 ± 1.70; range: 3.0 - 9.0). Significant differences were observed in the FoxP3 expression between mild (2.61 ± 0.98; range: 1.0 - 5.0) and moderate bronchial asthma (1.16 ± 0.60; range: 0.3 - 2.0) (p = 0.0001). This reduction of FoxP3 was extended and confirmed by flow cytometry, showing decreased proportions of CD4+CD25highFoxP3+ cells in the CD4+ cell population of the mild (0.85 ± 0.48; range: 0.2 - 2.0) and moderate (0.80 ± 0.39; range: 0.4 - 1.7) bronchial asthma patients compared to healthy children (2.33 ± 0.83; range: 0.98 - 3.9) (Figures 1B and 1C). Values of CD4+CD25highFoxP3+ cells in the CD4+ cell population were also expressed in absolute number [(mean ± SD) x106/mL]. The decreased CD4+CD25highFoxP3+ cells in mild asthmatics (0.047 ± 0.023) and in moderate asthmatics (0.044 ± 0.021) were maintained when values were expressed as absolute values compared to healthy controls (0.13 ± 0.046). No significant differences were observed between mild and moderate asthmatics when values were expressed as absolute values.
Figure 1

Antigen expression of t cells in healthy children and patients with mild and moderate bronchial asthma. Expression of forkhead box P3 (FoxP3) mRNA in T cells (A) and proportions of CD4+CD25highFoxP3+ cells in the CD4+ cell population (B), among healthy children and patients with mild and moderate bronchial asthma. Medians are indicated by a line inside each box, the 25th and 75th percentiles by the box limits, the lower and upper error bars represent the 10th and 90th percentiles, respectively. (C): CD4+CD25high and CD4+CD25high forkhead box P3 (FoxP3)+ cells in one representative moderate bronchial asthma children as measured by flow cytometry. Boxes (a) indicate cells in the CD25high population. Quadrants (b) indicate CD25highversus CD25low/intermediate cells and FoxP3+versus FoxP3- cells.

Alternative activation in monocytes/macrophages induced by Treg cells

A previously uncharacterized function of Treg cells, namely their ability to steer monocyte differentiation toward alternatively activated macrophages (AAM) has been recently depicted [10]. AAM are cells with strong anti-inflammatory potential involved in immune regulation, tissue remodeling, and parasite killing. We investigated 10 healthy controls and 7 moderate asthmatics.

To investigate whether CD4+CD25+ Treg cells from patients with bronchial asthma can steer the differentiation of monocytes to AAM, CD14+ monocytes isolated from peripheral blood mononuclear cells from moderate asthmatics were cultured alone, with autologous CD4+CD25- or CD4+CD25+ T cells. We used the same methodology reported by Tiemessen et al. [10]. Anti-CD3 mAb was present in all conditions to stimulate T cells. After 40 h, cells were collected for flow cytometry.

Figures 2A and 2B show that, relative to control monocytes, Treg-treated monocytes displayed astrong up-regulation of the typical AAM markers CD206 (n = 15, p < 0.05) and CD163 (n = 7, p < 0.02). The increased expression of CD206 and CD163 was greater in moderate asthmatics than in healthy controls, when monocytes were co-cultured with CD4+CD25+ (Figures 2A, B). We also determined the presence of CCL18, a chemokine that is specifically overexpressed by AAM [15], and found this to be significantly enhanced in monocyte/Treg co-cultures in asthmatics when compared to healthy controls (Figure 2C).
Figure 2

Treg cells induction of an alternative activated phenotype in monocytes/macrophages of moderate asthma children and controls. Monocytes were cultured without T cells (monocytes), with CD4+CD25- T cells, or with CD4+CD25+ T cells in the presence of anti-CD3 mAb (50 ng/ml). Moderate asthma = white bars; healthy controls = black bars. (A and B): The phenotype of monocytes was assessed after 40 h of culture by flow cytometry. The expression (average mean fluorescence intensity, MFI ± SEM) of CD206 and CD163 is shown for ten independent experiments, respectively. (C): The amount of CCL18 produced during the 40 h of co-culture was analyzed in the supernatant by ELISA. Significant differences were observed between moderate asthmatic children and control healthy children.

CD4+CD25+ Tregs from moderate asthma did not inhibit the proinflammatory response of monocytes/macrophages to LPS

Next we determined the ability of Treg-treated monocytes/macrophages from moderate asthmatics to respond to LPS. We investigated 10 healthy controls and 7 moderate asthmatics. As shown in Figures 3A, B and 3C monocytes cultured in the presence of CD4+CD25- effector T cells displayed increased production of proinflammatory cytokines. To exclude possible contributions of T cell-derived cytokines in these assays, we repeated these experiments twice with monocytes that were repurified after Treg co-culture and obtained similar results.
Figure 3

Failure to suppress the lps-induced proinflammatory response of monocytes/macrophages by treg cells in moderate bronchial asthma. Monocytes were cultured as described in the legend of Figure 2. After 40 h of co-culture, LPS (50 ng/ml) was added and 24 h later cytokine production was measured by ELISA (IL-6, TNF-α) or Luminex (IL-1β). The average production of ten independent experiments ± SD of proinflammatory cytokines is shown for the three culture conditions. Significant differences are seen in the graphs between moderate asthmatic children and healthy children. Moderate asthma = white bars; healthy controls = black bars.

Following co-culture of monocytes from healthy controls with autologous CD4+ CD25+ FoxP3+ Treg cells, there was significant suppression in their capacity to produce proinflammatory cytokines IL- 1β (Figure 3A), TNF-α (Figure 3B) and IL-6 (Figure 3C) compared to monocytes cultured alone. In patients with moderate asthma, monocytes cultured alone produced more IL-1β, TNF-α and IL-6 than monocytes from healthy controls. Co-culture of monocytes from moderate asthmatic CD4+ CD25+ FoxP3+ Treg cells failed to suppress TNF-α, IL-6 and IL-1β production.

Increased expression of Treg cells in induced sputum in patients with moderate asthma after treatment with inhaled corticosteroid

Eight patients with moderate asthma were investigated for Treg expression before and after 6 weeks treatment.

They received a stepwise treatment after enrollment, including inhaled corticosteroid (budesonide) and β2-agonists, as recommended by GINA [11]. Six weeks later, the patients were revisited. They were completely controlled regarding asthmatic symptoms after treatment according to the Asthma Control Test http://www.asthmacontrol.com. Induced sputum was collected again. Changes of CD25highFoxP3+ cells in the CD4+ cell population were measured and compared to values obtained before the treatment. CD4+CD25high T cell percentages were increased as reported in Figure 4.
Figure 4

Changes in proportions of cd4 + cd25 high foxp3 + cells in the cd4 + cell population from eight patients with moderate asthma, before and after treatment. Eight patients received treatment with inhaled corticosteroid and were revisited after 6 weeks. Proportions of CD4+CD25highFoxP3+ cells in the CD4+ cell population were slightly raised, and the difference between before (mean ± SD: 0.85 ± 0.43) and after (1.32 ± 0.63) treatment with optimal inhaled corticosteroid reached a statistically significant level (p = 0.0035).

Discussion

In the present study we found decreased proportions of CD4+CD25highFoxP3+ cells in induced sputum of the bronchial asthmatic groups, particularly in patients with moderate asthma, indicating low numbers of Treg cells compared to healthy children. We believe that using the combination of CD4+CD25high with FoxP3 as a marker of Treg cells will reflect more accurately the true numbers of Treg cells in induced sputum from asthmatics. In this study, the decreased proportions of CD4+CD25highFoxP3+ cells in mild and moderate asthma patients compared to healthy controls is supported by low expression of FoxP3 mRNA in CD3+ cells in the same patients. We also provide evidence for a previously uncharacterized role of human CD4+CD25+FoxP3+Treg cells, their ability to steer differentiation of monocytes toward AAMs. The expression of CD206, CD163 and CCL18 production was increased in moderate asthmatics than in healthy controls, when monocytes were co-cultured with CD4+CD25+.

To confirm the concept that treatment with inhaled corticosteroid could increase the frequency of peripheral CD4+CD25high T cells, we compared the quantitative change of this cell subset in 8 patients with moderate asthma before and after 6 weeks of inhaled corticosteroids. Although the increase after the treatment was slight, it was statistically significant. We speculate that dosage and course of the treatment may influence the final results. Further investigations are therefore needed to clarify this issue in asthma. Recently Zhang et al. [16] reported a slight increase of Treg cells after 4 weeks of inhaled budesonide treatment, but the difference observed before and after treatment was not statistically significant.

The frequency and phenotypic characteristics of CD4+, FoxP3+ T cells as well as their capacity to suppress inflammatory cytokine production and proliferation of CD4+, CD25- T cells (target cells) were comparable in young (age ≤ 40 years) and elderly (age ≥ 65 years) individuals. However, when CD4+, FoxP3+ Treg and CD4+, CD25-T cells were co-cultured, the production of anti-inflammatory cytokine IL-10 from CD4+, CD25- T cells was more potently suppressed in the elderly than in the young. This finding was not due to changes in cytotoxic T lymphocyte antigen (CTLA)-4 expression or apoptosis of CD4+, FoxP3+ Treg and CD4+, CD25- T cells. Taken together, these data [17] suggested that aging may affect the capacity of CD4+, FoxP3+ T cells to regulate IL-10 production from target CD4+ T cells in humans although their other cellular characteristics remain unchanged. We can speculate that no significant differences are observed between young and adult asthmatics in their peripheral blood circulation. However, no data were found concerning values of Treg cells in adult induced sputum. Homeostasis of Treg is controlled by several factors, among them the circulation and possibly their redistribution to extra-vascular tissue [18]. We can only speculate which factors contribute to decreased percentages of Tregs in induced sputum of asthmatics.

The role of IL-10 and transforming growth factor (TGF) has been suggested in the Treg-mediated regulation of T cell responses in vivo [19, 20]. Treg cells produce IL-10 or TGF-β or both, by which they attain most of their suppressive activity. IL-10 production suppresses exaggerated Th2 reactions. It inhibits directly and indirectly the activity of mast cells, basophils and eosinophils [21]. Peripheral blood analysis in asthmatics failed to reveal modification in absolute numbers of CD4+CD25+ T cells. However, bronchoalveolar lavage fluid of asthmatic children possessed significantly diminished levels of CD4+CD25+ T cells, IL-10 and TGF-β mRNA expression [22].

After administration of IL-2:anti-IL-2 complexes before and after allergenic stimulation, a remarkable increase in Treg counts was observed along with an increase in mRNA and IL-10 levels in lung tissue; in addition, subjects displayed decreased pulmonary pathologic findings (mucus secretion, airway inflammation and hyper-responsiveness [23]. Recent data from Matsumoto et al. [24] raised the possibility that lung CD4+CD25+FoxP3+ Treg cells may regulate asthma phenotype. The frequency of CD4+CD25+FoxP3+ Treg cells among CD4+CD25+ T cells in peripheral blood of asthmatics and in murine asthma model was significantly lower than that of healthy subjects [24].

Our data in asthmatics show that CD206, CD163 and CCL18 were increased compared to healthy controls. These findings indicate that Treg-mediated up-regulation of the macrophage mannose receptor may involve a novel pathway that depends on cell contact in controls and more so in asthmatics. Our data in healthy controls were in accordance with those reported by Tiemessen et al. [10]. Our data suggest that CD4+CD25+ Treg cells from moderate asthmatics exhibit a loss of suppression inducing production of high levels of proinflammatory cytokines (IL-1, IL-6 and TNF-α), contrasting with data obtained in healthy controls. According to all the reported data, we can speculate that the low suppressive activity of Treg cells in moderate asthma could be due in part to dysregulated cytokine production [21].

AAM are cells with strong anti-inflammatory potential involved in immune regulation and tissue remodeling [23]. Co-culture of Treg cells with monocytes/macrophages displays typical features of AAM, including up-regulated expression of CD206 (macrophage mannose receptor) and CD163 (hemoglobin scavenger receptor), an increased production of CCL18, and an enhanced phagocytic capacity. In addition, the monocytes/macrophages have reduced expression of HLA-DR and a strongly reduced capacity to respond to LPS in terms of proinflammatory mediator production (IL-1β, IL-6, IL-8, MIP-1α, TNF-α), nuclear factor (NF)-κB activation, and tyrosine phosphorylation [10, 25]. Mechanistic studies reveal that CD4+CD25+FoxP3+ Tregs produce IL-10, IL-4, and IL-13 and that these cytokines are the critical factors involved in the suppression of the proinflammatory cytokine response [10, 25]. CD4+CD25+ Tregs down-regulate proinflammatory cytokine production (IFN-γ and TNF-α), and directly inhibit IL-2 mRNA transcription. In vitro, the mechanism behind T cell suppression appears to be independent of IL-10 and TGF-β and based on cell contact between Tregs and responder T cells. Treg-mediated suppression in vivo involves multicellular clusters consisting of responder T cells, APC, and regulatory T cells, and during these cellular interactions membrane-bound and/or soluble inhibitory molecules contribute to suppression [10, 25].

The present study is, to our knowledge, the first demonstration of decreased proportions of Treg cells in induced sputum from mild and moderate asthmatic children. Our findings in the present study, showing markedly decreased proportions of CD4+CD25highFoxP3+ cells in young asthmatic patients, suggest that deficient immune regulation is an early event in this pathology. However, further studies are needed to clarify (i): how this Treg abnormality contributes to asthma severity, (ii): the strength correlation between monocytes/macrophages and Treg cells, (iii): the production of IL-10 and TGF-β by bronchial Treg cells. The role of T cells in asthma is complex and probably tightly regulated by the microenvironment.

Conflict of interest statement

None of the authors has any conflict of interest to declare in relation to the subject matter of this manuscript.

Declarations

Acknowledgements

The authors thank Ms Neziha Ben Hamida (Research Institute for Cancerology, Tunis) for technical assistance and Ms Francesca Mirti for translating the abstract into Italian. This work was supported by the Ministry of Research and Technology of Tunisia, DGRST Staff.

Authors’ Affiliations

(1)
Medicine Faculty, University of Tunis, Homeostasis and Cell Dysfunction (UR/99/08-40)
(2)
Department of Respiratory Diseases, Pavillon B, A. Mami Hospital

References

  1. Saglani S, Payne DN, Zhu J, Wang Z, Nicholson AG, Bush A, Jeffery PK: Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. Am J Respir Crit Care Med. 2007, 176: 858-864. 10.1164/rccm.200702-212OC.View ArticlePubMedGoogle Scholar
  2. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Panizzolo C, Zanin ME, Zuin R, Maestrelli P, Fabbri LM, Saetta M: Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med. 2006, 174: 975-981. 10.1164/rccm.200602-189OC.View ArticlePubMedGoogle Scholar
  3. Pohunek P, Warner JO, Turzíková J, Kudrmann J, Roche WR: Markers of eosinophilic inflammation and tissue re-modelling in children before clinically diagnosed bronchial asthma. Pediatr Allergy Immunol. 2005, 16: 43-51. 10.1111/j.1399-3038.2005.00239.x.View ArticlePubMedGoogle Scholar
  4. Afshar R, Medoff BD, Luster AD: Allergic asthma: a tale of many T cells. Clin Exp Allergy. 2008, 38: 1847-1857. 10.1111/j.1365-2222.2008.03119.x.View ArticlePubMedGoogle Scholar
  5. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA: Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med. 2004, 199: 1567-1575. 10.1084/jem.20032058.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Strickland DH, Stumbles PA, Zosky GR, Subrata LS, Thomas JA, Turner DJ, Sly PD, Holt PG: Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J Exp Med. 2006, 203: 2649-2660. 10.1084/jem.20060155.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, Schendel DJ, Griese M, Krauss-Etschmann S: Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. J Allergy Clin Immunol. 2007, 119: 1258-1266. 10.1016/j.jaci.2007.02.023.View ArticlePubMedGoogle Scholar
  8. Curotto de Lafaille MA, Kutchukhidze N, Shen S, Ding Y, Yee H, Lafaille JJ: Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity. 2008, 29: 114-126. 10.1016/j.immuni.2008.05.010.View ArticlePubMedGoogle Scholar
  9. Buechler C, Ritter M, Orsó E, Langmann T, Klucken J, Schmitz G: Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by proand antiinflammatory stimuli. J Leukoc Biol. 2000, 67: 97-103.PubMedGoogle Scholar
  10. Tiemessen MM, Jagger AL, Evans HG, John S, Taams LS: CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA. 2007, 104: 19446-19451. 10.1073/pnas.0706832104.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA) 2008. [http://www.ginasthma.org]
  12. Hamzaoui A, Cheik Rouhou S, Graïri H, Abid H, Ammar J, Chelbi H, Hamzaoui K: NKT cells in the induced sputum of severe asthmatics. Mediators of Inflammation. 2006, 2006: 71214-PubMed CentralView ArticlePubMedGoogle Scholar
  13. Hamzaoui K, Houman H, Hamzaoui A: Regulatory T cells in cerebrospinal fluid from Behçet's disease with neurological manifestations. J Neuroimmunol. 2007, 187: 201-204.View ArticlePubMedGoogle Scholar
  14. Hamzaoui K, Hamzaoui A, Houman H: CD4+CD25+ regulatory T cells in patients with Behçet's disease. Clin Exp Rheumatol. 2006, 24 (5 Suppl 42): S71-78.PubMedGoogle Scholar
  15. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, Goerdt S: Alternative macrophage activation-associated CCchemokine- 1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol. 1998, 160: 1411-1418.PubMedGoogle Scholar
  16. Zhang Q, Qian FH, Liu H, Zhou LF, Huang M, Zhang XL, Yin KS: Expression of surface markers on peripheral CD4+CD25high T cells in patients with atopic asthma: role of inhaled corticosteroid. Chin Med J. 2008, 121: 205-212.PubMedGoogle Scholar
  17. Hwang KA, Kim HR, Kang I: Aging and human CD4(+) regulatoryregulatory T cells. Mech Ageing Dev. 2009, 130: 509-517. 10.1016/j.mad.2009.06.003.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Wei S, Kryczek I, Zou W: Regulatory T-cell compartmentalization and trafficking. Blood. 2006, 108: 426-431. 10.1182/blood-2006-01-0177.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Jiang H, Chess L: Regulation of immune responses by T cells. N Engl J Med. 2006, 354: 1166-1176. 10.1056/NEJMra055446.View ArticlePubMedGoogle Scholar
  20. Nandakumar S, Miller CW, Kumaraguru U: T regulatory cells: an overview and intervention techniques to modulate allergy outcome. Clin Mol Allergy. 2009, 7: 5-10.1186/1476-7961-7-5.PubMed CentralView ArticlePubMedGoogle Scholar
  21. Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM: Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006, 118: 1-9. 10.1111/j.1365-2567.2006.02348.x.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Hartl D, Griese M, Nicolai T, Zissel G, Prell C, Konstantopoulos N, Gruber R, Reinhardt D, Schendel DJ, Krauss-Etschmann S: Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. J Allergy Clin Immunol. 2005, 115: 728-736. 10.1016/j.jaci.2004.11.049.View ArticlePubMedGoogle Scholar
  23. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J: Selective stimulation of T cell subsets with antibodycytokine immune complexes. Science. 2006, 311: 1924-1927. 10.1126/science.1122927.View ArticlePubMedGoogle Scholar
  24. Matsumoto K, Inoue H, Fukuyama S, Kan-O K, Eguchi- Tsuda M, Matsumoto T, Moriwaki A, Nakano T, Nakanishi Y: Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma. Respirology. 2009, 14: 187-194. 10.1111/j.1440-1843.2008.01472.x.View ArticlePubMedGoogle Scholar
  25. Taams LS, van Amelsfort JM, Tiemessen MM, Jacobs KM, de Jong EC, Akbar AN, Bijlsma JW, Lafeber FP: Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol. 2005, 66: 222-230. 10.1016/j.humimm.2004.12.006.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Novamedia srl 2010